Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure

Table 1 Clinical data

Factors	Dialysis group (n = 45)	Joint group (n = 49)	χ2 value	P value
Age (yr)			2.042	0.153
> 60	25	20
≤ 60	20	29
Gender			0.641	0.423
Male	22	28
Female	23	21
BMI (kg/m2)			0.300	0.583
> 25	15	19
≤ 25	30	30
Course of renal decompensation (yr)			0.526	0.468
> 2	29	35
≤ 2	16	14
History of hypertension			0.512	0.474
Yes	12	10
No	33	39
History of hyperlipidemia			0.566	0.451
Yes	8	6
No	37	43
History of smoking			0.641	0.423
Yes	22	28
No	23	21
History of alcoholism			0.222	0.637
Yes	6	5
No	39	44

BMI: Body mass index.

Table 2 Efficacy evaluation, n (%)

Group	Markedly effective	Effective	Ineffective	Total effective rate
Dialysis group (n = 45)	25 (55.56)	8 (17.78)	12 (26.66)	33 (73.34)
Joint group (n = 49)	33 (67.35)	12 (24.48)	4 (8.16)	45 (91.84)
χ2 value				5.686
P value				0.017

Table 3 Adverse reactions, n (%)

Group	Nausea and vomiting	Loss of appetite	Phlebitis	Gastrointestinal reaction	Rash	Total incidence rate
Dialysis group (n = 45)	2 (4.44)	2 (4.44)	1 (2.22)	2 (4.44)	1 (2.22)	8 (17.78)
Joint group (n = 49)	1 (2.04)	1 (2.04)	2 (4.08)	1 (2.04)	1 (2.04)	6 (12.24)
χ2 value						0.566
P value						0.451